Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NephrosNEPH +4.65%76 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates NEPH with a GF Score™ of 76/100 and a GF Value™ of $3.27 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Nephros ranks worse than 145348.69% on this metric.
During the past 12 months, Nephros's average EBITDA Per Share Growth Rate was 17.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nephros was 57.00% per year. The lowest was -82.90% per year. And the median was 24.25% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Nephros 3-Year EBITDA Growth Rate Related Terms
NEPH vs POCI, MLSS, DXR: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Nephros's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nephros 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nephros's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nephros's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Nephros (NEPH) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nephros and its competitors. According to the industry distribution chart, Nephros ranks #999999 out of 688 companies in the Medical Devices & Instruments industry.
Is Nephros' 3-Year EBITDA Growth Rate too high?
Nephros' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Nephros ranks #999999 out of 688 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nephros has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' 3-Year EBITDA Growth Rate compare to POCI and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Nephros ranks #999999 out of 688 companies for 3-Year EBITDA Growth Rate. This places Nephros in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nephros and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nephros's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.27, compared to a current price of $4.38 — trading 33.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Nephros' overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nephros (NEPH), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nephros (NEPH) Overvalued in 2026?
Based on GuruFocus' analysis, Nephros stock appears to be overvalued.
The current stock price of $4.38 is trading 33.8% above its estimated GF Value™ of $3.27.
GuruFocus considers Nephros to be Significantly Overvalued.
Key valuation signals for NEPH:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: $3.27 vs. price of $4.38 (33.8% above fair value)
No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
76GF Score
Get the complete analysis for NEPH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEPH has been successfully added to your 
